CPA
GSK icon

Capital Performance Advisors’s GSK GSK Stock Holding History

Capital Performance Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,649
Closed -$257K – 390
2026
Q1 		$257K Buy
4,649
+393
+9% +$21.3K 0.02% 367
2025
Q4 		$209K Buy
+4,256
New +$199K 0.01% 415
2024
Q4 		– Sell
-353
Closed -$14.4K – 1190
2024
Q3 		$14.4K Buy
+353
New +$14.4K ﹤0.01% 700

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Capital Performance Advisors's GSK Position: Q2 2026 in Review

Capital Performance Advisors sold out of GSK (GSK) in Q2 2026, closing a stake of 4,649 shares — an estimated $257K sold.

Capital Performance Advisors first reported a position in GSK in Q3 2024 and held it in 3 quarters. The position peaked at $257K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Capital Performance Advisors reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 4,649 GSK shares in Q2 2026, an estimated $257K.
  • Capital Performance Advisors first reported a position in GSK in Q3 2024 and held it in 3 quarters.
  • Capital Performance Advisors's GSK position peaked at $257K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.